Clinical research on Lidantuihuang Prescription in the treatment of viral cholestatic hepatitis

Objective To evaluate the clinical efficacy and safety of Lidantuihuang Prescription in the treatment of liver and gallbladder damp-heat syndrome of cholestatic viral hepatitisease. Methods A multicenter, randomized, controlled parallel study was conducted with 55 patients involved, which were divided into two groups. The control group(27 cases) was treated with Liver JiangMei+oral ursodeoxycholic acid 250 mg, bid, and the treatment group(28 cases) applied the same basic treatments and the Chinese decotion for 4 weeks. Changes in clinical comprehensive efficacy, TCM syndromes, and liver function [total bilirubin(TB), direct bilirubin(DB), alanine aminotransferase(ALT), γ-glutamyl transpeptidase(GGT), alkaline phosphatase(ALP) were observed. Results The treatment group was significantly better than the control group in clinical efficacy, TCM syndrome, P0.05. The blood serum levels of TB, DB, ALT, AST, ALP in treatment group were(37.91±21.30) μmol/L,(23.70±18.49) μmol/L,(40.50±13.90) μmol/L,(64.30 ± 17.80) μ mol/L,(125.60 ± 21.30) μ mol/L, all significantly lower than those in the control group:(78.96 ±34.48) μmol/L,(66.40±30.28) μmol/L,(68.60±24.80) μmol/L,(90.10±27.80) μmol/L,(157.49±36.49) μmol/L, P0.05. Safety indexes such as blood test, urine test, renal function and electrocardiogram showed no adverse events.Conclusion Lidantuihuang Prescription is efficient and safe for jaundice and liver-gallbladder damp-heat syndrome in cholestatic hepatitis virus, which is worthy of clinical promotion.